Queensland refuses to reconsider trans medicine ban

4 minute read


Despite the federal health minister urging otherwise, the northern state will not be re-examining its ban on puberty blockers for young people with gender dysphoria. 


The country’s top research body may have provisionally recommended prescribing puberty suppressants to young trans and gender diverse Australians, but Queensland’s health minister says the state’s position on the drugs remains unchanged.  

On Monday, federal health minister Mark Butler announced that the National Health and Medical Research Council had released interim advice conditionally recommending the consideration of gonadotropin-releasing hormone agonists for patients with gender congruence under the age of 18.  

It came with several caveats, including that the young person has been diagnosed with gender incongruence, has commenced puberty (defined as Tanner stage 2 or later), and is assessed as suitable for treatment in collaboration with clinicians.  

It also emphasised the importance of shared decision making between the patient, their parent or guardian, and the treating clinician.  

Mr Butler urged both Queensland and the Northern Territory to reconsider existing bans on public hospital puberty blocker prescriptions in light of the recommendation.  

“The Queensland Government has already undertaken an independent review and made a clear decision on the provision of these treatments in our public hospitals,” a spokesperson for Queensland health minister Tim Nicholls said. 

“Our position remains unchanged, and we will continue to prioritise the health, safety and wellbeing of young Queenslanders.”  

The Queensland government banned the prescription of puberty blockers in public hospital gender clinics in 2025, pending the results of the UK PATHWAYS TRIAL, which are not expected until 2031.  

The ban was initiated despite a government-commissioned independent review highlighting that this course of action would not strengthen research or monitor quality of care and carried other legal, ethical, and social risks related to equitable access to care.  

AMA Queensland president Associate Professor Erica Gannon said the minister’s decision to ban the use of puberty blockers has “caused, and continues to cause, significant harm to children, their families and the clinicians who treat them”.  

“AMA Queensland has consistently called on the government to act in accordance with science, not ideological belief,” she told The Medical Republic.  

“These are case by case medical decisions that should be made by patients and, where appropriate, their families, together with their medical team. 

“Since the start of the ban, we have urged the Minister to follow the advice of the NHMRC as the most appropriate body to determine this matter. 

“We again urge the government to follow the NHMRC’s advice now and reverse the ban.”  

The Australian Professional Association for Trans Health (AusPATH) and LGBITQ+ Health Australia both welcomed the provisional NHMRC guidance.  

“The use of puberty suppressants is one possible part of care, not the entirety of care, and it is not necessary to wait until a young person is distressed before providing care,” AusPATH CEO Eloise Brook said. 

“The Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents developed by the Royal Children’s Hospital Melbourne provide an important framework for clinical practice in Australia.  

“The NHMRC’s interim advice is a valuable addition that supports continuing evidence-informed decision-making, clinical governance and high-quality care.  

“It reflects the ongoing evolution of clinical practice and healthcare guidance in gender affirming care, consistent with clinical guideline development processes across all areas of health.” 

“As with all NHMRC guidelines, recommendations are informed by the best available evidence currently available and are updated as new evidence emerges. This advice provides an important foundation for continued evidence review, clinical excellence and high-quality care.” 

Ms Brook said she “encouraged” jurisdictions where access to care was limited to “consider the NHMRC’s advice”.  

“Consistency in healthcare delivery is important to ensure young people and families can access appropriate support, irrespective of where they live,” she said.  

The NHMRC advice will be open to consultation until early 2027.  

End of content

No more pages to load

Log In Register ×